Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015

Drugs taken for cancer can interact with each other, with agents taken as part of supportive care, with drugs taken for comorbid conditions (which are particularly common in the elderly patients), and with herbal supplements and complementary medicines. We tend to focus on the narrow therapeutic win...

Full description

Saved in:
Bibliographic Details
Published in:Ecancermedicalscience 2016-01, Vol.10, p.611-611
Main Authors: Stepney, Rob, Lichtman, Stuart M, Danesi, Romano
Format: Article
Language:English
Subjects:
Age
Androgens
Cancer therapies
Conference Report
Drugs
Enzymes
Geriatrics
Metabolism
Metabolites
Oncology
Polypharmacy
Professionals
Prostate cancer
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c424t-b309037c5993391307f42562de7b7b75b214a5d5c9410ccb77c3975c92073cb53
cites
container_end_page 611
container_issue
container_start_page 611
container_title Ecancermedicalscience
container_volume 10
creator Stepney, Rob
Lichtman, Stuart M
Danesi, Romano
description Drugs taken for cancer can interact with each other, with agents taken as part of supportive care, with drugs taken for comorbid conditions (which are particularly common in the elderly patients), and with herbal supplements and complementary medicines. We tend to focus on the narrow therapeutic window of cytotoxics, but the metabolism of tyrosine kinase inhibitors by the cytochrome P450 3A4 enzyme (CYP3A4) makes some TKIs particularly prone to interference with or from other agents sharing this pathway. There is also potential for adverse pharmacokinetic interactions with new hormonal agents used in advanced prostate cancer.
doi_str_mv 10.3332/ecancer.2016.611
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4720490</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1761472681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-b309037c5993391307f42562de7b7b75b214a5d5c9410ccb77c3975c92073cb53</originalsourceid><addsrcrecordid>eNpdUktv1DAQthCItgt3TsgSFw6brR-xveGAhBZaKlUU8ThbjjPZdZXEi-0Ubf8V_7AOu1SlsmTPeL755qEPoVeULDjn7BSsGSyEBSNULiSlT9AxVaIspCTi6QP7CJ3EeE2IpBUTz9ERk0vG5ZIcoz8fw7gumnxhNyQIxibnh5gd7LsGAt6a5GBIEf92aYP39d5hgwNsfUi4Db7HaQOYihxe-aGFABmDffv3-2IiHcxEajr83VsHaTcFzyE4k4Kz-GqwvvPr3Rx_DWY9whyvbsFu8DfYjnXn7Bx_8TfQ17mZPKd4gZ61povw8vDO0M-zTz9Wn4vLq_OL1YfLwpasTEXNSUW4sqKqOK8oJ6otmZCsAVXnI2pGSyMaYauSEmtrpSyvVHYZUdzWgs_Q-z1v7qKHxuYlBNPpbXC9CTvtjdP_Rwa30Wt_o0vFSJlrz9DbA0Hwv0aISfcuWug6M4Afo6ZK0oyVS5qhbx5Br_2Y19ZlVCU4k7xcqowie5QNPsYA7X0zlOhJD_qgBz3pQWc95JTXD4e4T_gnAH4HCLqzxw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1953263487</pqid></control><display><type>article</type><title>Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Stepney, Rob ; Lichtman, Stuart M ; Danesi, Romano</creator><creatorcontrib>Stepney, Rob ; Lichtman, Stuart M ; Danesi, Romano</creatorcontrib><description>Drugs taken for cancer can interact with each other, with agents taken as part of supportive care, with drugs taken for comorbid conditions (which are particularly common in the elderly patients), and with herbal supplements and complementary medicines. We tend to focus on the narrow therapeutic window of cytotoxics, but the metabolism of tyrosine kinase inhibitors by the cytochrome P450 3A4 enzyme (CYP3A4) makes some TKIs particularly prone to interference with or from other agents sharing this pathway. There is also potential for adverse pharmacokinetic interactions with new hormonal agents used in advanced prostate cancer.</description><identifier>ISSN: 1754-6605</identifier><identifier>EISSN: 1754-6605</identifier><identifier>DOI: 10.3332/ecancer.2016.611</identifier><identifier>PMID: 26823680</identifier><language>eng</language><publisher>England: Cancer Intelligence</publisher><subject>Age ; Androgens ; Cancer therapies ; Conference Report ; Drugs ; Enzymes ; Geriatrics ; Metabolism ; Metabolites ; Oncology ; Polypharmacy ; Professionals ; Prostate cancer</subject><ispartof>Ecancermedicalscience, 2016-01, Vol.10, p.611-611</ispartof><rights>the authors; licensee ecancermedicalscience. 2016. This work is licensed under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>the authors; licensee ecancermedicalscience. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-b309037c5993391307f42562de7b7b75b214a5d5c9410ccb77c3975c92073cb53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1953263487/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1953263487?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26823680$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stepney, Rob</creatorcontrib><creatorcontrib>Lichtman, Stuart M</creatorcontrib><creatorcontrib>Danesi, Romano</creatorcontrib><title>Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015</title><title>Ecancermedicalscience</title><addtitle>Ecancermedicalscience</addtitle><description>Drugs taken for cancer can interact with each other, with agents taken as part of supportive care, with drugs taken for comorbid conditions (which are particularly common in the elderly patients), and with herbal supplements and complementary medicines. We tend to focus on the narrow therapeutic window of cytotoxics, but the metabolism of tyrosine kinase inhibitors by the cytochrome P450 3A4 enzyme (CYP3A4) makes some TKIs particularly prone to interference with or from other agents sharing this pathway. There is also potential for adverse pharmacokinetic interactions with new hormonal agents used in advanced prostate cancer.</description><subject>Age</subject><subject>Androgens</subject><subject>Cancer therapies</subject><subject>Conference Report</subject><subject>Drugs</subject><subject>Enzymes</subject><subject>Geriatrics</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Oncology</subject><subject>Polypharmacy</subject><subject>Professionals</subject><subject>Prostate cancer</subject><issn>1754-6605</issn><issn>1754-6605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdUktv1DAQthCItgt3TsgSFw6brR-xveGAhBZaKlUU8ThbjjPZdZXEi-0Ubf8V_7AOu1SlsmTPeL755qEPoVeULDjn7BSsGSyEBSNULiSlT9AxVaIspCTi6QP7CJ3EeE2IpBUTz9ERk0vG5ZIcoz8fw7gumnxhNyQIxibnh5gd7LsGAt6a5GBIEf92aYP39d5hgwNsfUi4Db7HaQOYihxe-aGFABmDffv3-2IiHcxEajr83VsHaTcFzyE4k4Kz-GqwvvPr3Rx_DWY9whyvbsFu8DfYjnXn7Bx_8TfQ17mZPKd4gZ61povw8vDO0M-zTz9Wn4vLq_OL1YfLwpasTEXNSUW4sqKqOK8oJ6otmZCsAVXnI2pGSyMaYauSEmtrpSyvVHYZUdzWgs_Q-z1v7qKHxuYlBNPpbXC9CTvtjdP_Rwa30Wt_o0vFSJlrz9DbA0Hwv0aISfcuWug6M4Afo6ZK0oyVS5qhbx5Br_2Y19ZlVCU4k7xcqowie5QNPsYA7X0zlOhJD_qgBz3pQWc95JTXD4e4T_gnAH4HCLqzxw</recordid><startdate>20160114</startdate><enddate>20160114</enddate><creator>Stepney, Rob</creator><creator>Lichtman, Stuart M</creator><creator>Danesi, Romano</creator><general>Cancer Intelligence</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160114</creationdate><title>Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015</title><author>Stepney, Rob ; Lichtman, Stuart M ; Danesi, Romano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-b309037c5993391307f42562de7b7b75b214a5d5c9410ccb77c3975c92073cb53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Age</topic><topic>Androgens</topic><topic>Cancer therapies</topic><topic>Conference Report</topic><topic>Drugs</topic><topic>Enzymes</topic><topic>Geriatrics</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Oncology</topic><topic>Polypharmacy</topic><topic>Professionals</topic><topic>Prostate cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stepney, Rob</creatorcontrib><creatorcontrib>Lichtman, Stuart M</creatorcontrib><creatorcontrib>Danesi, Romano</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Ecancermedicalscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stepney, Rob</au><au>Lichtman, Stuart M</au><au>Danesi, Romano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015</atitle><jtitle>Ecancermedicalscience</jtitle><addtitle>Ecancermedicalscience</addtitle><date>2016-01-14</date><risdate>2016</risdate><volume>10</volume><spage>611</spage><epage>611</epage><pages>611-611</pages><issn>1754-6605</issn><eissn>1754-6605</eissn><abstract>Drugs taken for cancer can interact with each other, with agents taken as part of supportive care, with drugs taken for comorbid conditions (which are particularly common in the elderly patients), and with herbal supplements and complementary medicines. We tend to focus on the narrow therapeutic window of cytotoxics, but the metabolism of tyrosine kinase inhibitors by the cytochrome P450 3A4 enzyme (CYP3A4) makes some TKIs particularly prone to interference with or from other agents sharing this pathway. There is also potential for adverse pharmacokinetic interactions with new hormonal agents used in advanced prostate cancer.</abstract><cop>England</cop><pub>Cancer Intelligence</pub><pmid>26823680</pmid><doi>10.3332/ecancer.2016.611</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1754-6605
ispartof Ecancermedicalscience, 2016-01, Vol.10, p.611-611
issn 1754-6605
1754-6605
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4720490
source Open Access: PubMed Central; Publicly Available Content Database
subjects Age
Androgens
Cancer therapies
Conference Report
Drugs
Enzymes
Geriatrics
Metabolism
Metabolites
Oncology
Polypharmacy
Professionals
Prostate cancer
title Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T06%3A15%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug-drug%20interactions%20in%20older%20patients%20with%20cancer:%20a%20report%20from%20the%2015th%20Conference%20of%20the%20International%20Society%20of%20Geriatric%20Oncology,%20Prague,%20Czech%20Republic,%20November%202015&rft.jtitle=Ecancermedicalscience&rft.au=Stepney,%20Rob&rft.date=2016-01-14&rft.volume=10&rft.spage=611&rft.epage=611&rft.pages=611-611&rft.issn=1754-6605&rft.eissn=1754-6605&rft_id=info:doi/10.3332/ecancer.2016.611&rft_dat=%3Cproquest_pubme%3E1761472681%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c424t-b309037c5993391307f42562de7b7b75b214a5d5c9410ccb77c3975c92073cb53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1953263487&rft_id=info:pmid/26823680&rfr_iscdi=true